Jimmy Chun Yu Louie
The Nova classification organises foods by the extent and purpose of industrial processing, and its public-health corollary, that ultra-processed foods should be minimised, now shapes dietary guidelines and regulation. One clinically important product class challenges this framework. Oral nutritional supplements (ONS) and other foods for special medical purposes meet every Nova criterion for ultra-processed food, being industrial formulations of protein isolates, maltodextrin, refined oils, emulsifiers, stabilisers, flavourings and added micronutrients. Yet these same products are recommended by the European Society for Clinical Nutrition and Metabolism (ESPEN) and other clinical nutrition bodies for the prevention and treatment of disease-related malnutrition. The same product can therefore be discouraged under a processing-based framework yet prescribed under an outcomes-based one. This review examines that tension. It considers why ONS are unambiguously classified as Nova group 4 products, evaluates the clinical evidence, and explores why several product properties viewed as drawbacks at population level become therapeutic tools in clinical care. The evidence supports intake-level benefits consistently and clinical-endpoint benefits in defined malnourished populations, while remaining mixed for several hard outcomes; legitimate cautions about overreliance, fibre and dietary displacement deserve engagement rather than dismissal. The properties delivering benefit are compositional and contextual, with industrial processing serving as the means by which they are achieved. A context-aware framework is proposed that retains Nova as a population-level signal while making nutritional adequacy and clinical purpose the governing axes for individual care, with implications for guidelines, regulation and communication.